Results 11 to 20 of about 30,272 (291)

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma [PDF]

Frontiers in Immunology, 2023
Head and neck squamous cell carcinoma (HNSCC) is a major challenge for current therapies. CAR-T cells have shown promising results in blood cancers, however, their effectiveness against solid tumors remains a hurdle. Recently, CD44v6-directed CAR-T cells
Ioana Sonya Ciulean, Joe Fischer, Andrea Quaiser, Christoph Bach, Hinrich Abken, Uta Sandy Tretbar, Stephan Fricke, Ulrike Koehl, Ulrike Koehl, Dominik Schmiedel, Dominik Schmiedel, Thomas Grunwald   +11 more
doaj   +3 more sources

Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression [PDF]

Frontiers in Immunology
Allogeneic natural killer (NK) cell therapy has demonstrated significant potential in cancer immunotherapy by harnessing NK cells to target malignancies.
Dong-Hyeon Jo, Dong-Hyeon Jo, Shelby Kaczmarek, Shelby Kaczmarek, Abrar Ul Haq Khan, Abrar Ul Haq Khan, Jannat Pervin, Jannat Pervin, Diana M. Clark, Suresh Gadde, Suresh Gadde, Suresh Gadde, Lisheng Wang, Lisheng Wang, Lisheng Wang, Scott McComb, Scott McComb, Scott McComb, Scott McComb, Alissa Visram, Alissa Visram, Alissa Visram, Seung-Hwan Lee, Seung-Hwan Lee, Seung-Hwan Lee   +24 more
doaj   +3 more sources

CAR-NK cell therapy: promise and challenges in solid tumors. [PDF]

Front Immunol
Over the past few years, cellular immunotherapy has emerged as a promising treatment for certain hematologic cancers, with various CAR-T therapies now widely used in clinical settings. However, challenges related to the production of autologous cell products and the management of CAR-T cell toxicity highlight the need for new cell therapy options that ...
Balkhi S, Zuccolotto G, Di Spirito A, Rosato A, Mortara L.   +4 more
europepmc   +8 more sources

Breakthrough of solid tumor treatment: CAR-NK immunotherapy

Cell Death Discovery
As the latest and most anticipated method of tumor immunotherapy, CAR-NK therapy has received increasing attention in recent years, and its safety and high efficiency have irreplaceable advantages over CAR-T.
Wenkang Wang, Yang Liu, Zhen He, Lifeng Li, Senbo Liu, Mingqiang Jiang, Bing Zhao, Meng Deng, Wendong Wang, Xuefang Mi, Zhenqiang Sun, Xin Ge   +11 more
doaj   +3 more sources

CAR-NK cells: A promising cellular immunotherapy for cancer [PDF]

EBioMedicine, 2020
Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating ...
Guozhu Xie, Han Dong, Yong Liang, James Dongjoo Ham, Romee Rizwan, Jianzhu Chen   +5 more
doaj   +5 more sources

CAR NK Zelltherapie im Glioblastom: Effekte ionisierender Strahlung [PDF]

Einführung: Der häufigste primäre Hirntumor bei Erwachsenen ist das Glioblastom, welches durch ein aggressives Wachstum und eine schlechte Prognose gekennzeichnet ist. Zelluläre Immuntherapien haben in jüngster Vergangenheit große Erfolge bei der Behandlung von hämatologischen Tumoren erzielt. Jedoch blieb ein erfolgreicher Einsatz bei soliden Tumoren,
Prause, Lukas
openaire   +4 more sources

Single VHH-directed BCMA CAR-NK cells for multiple myeloma

Experimental Hematology & Oncology, 2023
Natural killer (NK) cells are promising alternatives for the production of “off-the-shelf” CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells.
Quan Ren, Yingling Zu, Hongchang Su, Qiumei Lu, Bin Xiang, Yanping Luo, Jishuai Zhang, Yongping Song   +7 more
doaj   +3 more sources

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy. [PDF]

Frontiers in oncology, 2021
The tumor microenvironment (TME) is greatly multifaceted and immune escape is an imperative attribute of tumors fostering tumor progression and metastasis. Based on reports, the restricted achievement attained by T cell immunotherapy reflects the prominence of emerging other innovative immunotherapeutics, in particular, natural killer (NK) cells-based ...
Marofi, Faroogh, Al-Awad, Alaa S., Sulaiman Rahman, Heshu, Markov, Alexander, Abdelbasset, Walid Kamal, Ivanovna Enina, Yulianna, Mahmoodi, Mahnaz, Hassanzadeh, Ali, Yazdanifar, Mahboubeh, Stanley Chartrand, Max, Jarahian, Mostafa   +10 more
openaire   +4 more sources

Advances in CAR-NK cell therapy for hematological malignancies [PDF]

Frontiers in Immunology
Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of hematological malignancies, demonstrably improving patient outcomes and prognosis. However, its application has introduced new challenges, such as safety concerns, off-target toxicities, and significant costs.
Rui Yang, Yun Yang, Yun Yang, Rui Liu, Yiwen Wang, Ruoyu Yang, Aili He, Aili He   +7 more
openaire   +5 more sources

Engineering the next generation of CAR-NK immunotherapies [PDF]

International Journal of Hematology, 2021
Over the past few years, cellular immunotherapy has emerged as a novel treatment option for certain forms of hematologic malignancies with multiple CAR-T therapies now routinely administered in the clinic. The limitations of generating an autologous cell product and the challenges of toxicity with CAR-T cells underscore the need to develop novel cell ...
Biederstädt, Alexander, Rezvani, Katayoun   +1 more
openaire   +2 more sources